Semaglutide and tirzepatide are the two most-studied incretin peptides in existence — and, unusually for this category, they have been compared head to head in a clinical trial. That makes this one of the very few comparisons in the peptide market that rests on direct evidence rather than cross-trial inference.
Semaglutide vs Tirzepatide at a Glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | Single agonist | Dual agonist |
| Receptors | GLP-1 | GIP · GLP-1 |
| Length | 31 amino acids | 39 amino acids |
| Developer | Novo Nordisk | Eli Lilly |
| Approved in Canada? | Yes — Ozempic, Wegovy, Rybelsus | Yes — Mounjaro, Zepbound |
| Generic in Canada? | Yes — first in the G7 | No |
| Oral form? | Yes — Rybelsus | No |
| Trial weight reduction | 14.9% at 68 weeks (STEP 1) | 20.9% at 72 weeks (SURMOUNT-1) |
| Trial doses | 0.5–2.4 mg weekly | 5 / 10 / 15 mg weekly |
| Half-life | ~7 days | ~5 days |
| Cardiovascular outcome data | Yes — SELECT | Not the primary record |
| Head-to-head trial? | Yes — SURMOUNT-5 | |
The Mechanism: One Receptor or Two
Semaglutide is a GLP-1 receptor agonist — a 31-amino-acid analog of native human GLP-1, modified with a C18 fatty diacid chain that binds albumin and extends its half-life from roughly two minutes to seven days. It acts on one receptor.
Tirzepatide is a 39-amino-acid peptide that binds two: GIP and GLP-1. The GLP-1 arm does approximately what semaglutide does. The GIP arm is the addition.
What GIP actually contributes is still debated
Three hypotheses appear in the literature, and none is settled:
- Central pathways — GIP receptors are expressed in brain regions governing food intake, and their distribution does not fully overlap with GLP-1 receptor distribution. The non-overlap may explain the additive effect.
- Adipose signaling — GIP receptors are present on fat cells, and agonism may act on adipose tissue directly.
- Tolerability — GIP agonism may blunt the nausea that limits GLP-1 dosing, permitting effective exposure at levels that would otherwise be intolerable. On this reading, the benefit is indirect: not a better mechanism, just a higher usable dose.
The third possibility is deflationary and rarely discussed, and it is not ruled out.
Receptor affinity is also asymmetric. Tirzepatide binds GIP with substantially higher potency than GLP-1 — it is often described as an “imbalanced” dual agonist. “Dual” understates how differently the two arms are engaged.
The Head-to-Head Trial: SURMOUNT-5
This is what makes this comparison different from every other one in the peptide market.
SURMOUNT-5 randomised 751 adults with obesity, without diabetes, to the maximum tolerated dose of tirzepatide or semaglutide, over 72 weeks. It is the first direct clinical comparison between a dual GIP/GLP-1 agonist and the leading GLP-1 monotherapy.
Tirzepatide produced greater weight reduction.
Almost every “X versus Y” claim in this market is cross-trial inference — taking a number from one trial and a number from another and treating the difference as meaningful. It usually isn’t. SURMOUNT-5 is one of the few places where the comparison was actually run.
Where Semaglutide Has the Deeper Record
Weight reduction is one axis. It is not the only one, and on the others semaglutide is ahead.
Cardiovascular outcomes. The SELECT trial examined major adverse cardiovascular events in participants with established cardiovascular disease and obesity, without diabetes. That is a hard outcome — a different class of evidence from a metabolic surrogate like weight or HbA1c. Tirzepatide’s record does not include an equivalent.
Real-world exposure. Semaglutide has been in broad clinical use for substantially longer.
Generics. Health Canada became the first G7 regulator to approve a generic semaglutide, with further submissions under review. There is no approved generic tirzepatide.
An oral formulation. Rybelsus. Tirzepatide is injectable only. Oral bioavailability for a peptide this size is very low, which is why the oral trial doses run an order of magnitude above the injectable ones — but it exists.
Side Effects Compared
Both compounds show the same class profile, and it is dominated by gastrointestinal effects: nausea, vomiting, and diarrhea, all dose-related. Both trial programmes escalated doses gradually for exactly this reason.
Health Canada documents the known risks of authorized GLP-1 products: severe gastrointestinal problems, pancreatitis, worsening kidney injury, and hypoglycemia.
No meaningful difference in the type of adverse effect is established between the two. The class profile is the class profile.
Regulatory Status in Canada
Both are approved prescription drugs in Canada, each carrying a Drug Identification Number:
- Semaglutide — Ozempic (T2D), Wegovy (weight management), Rybelsus (oral, T2D), plus approved generics.
- Tirzepatide — Mounjaro (T2D), Zepbound (weight management). No approved generic.
Anyone seeking either compound as a medication should obtain an authorized, DIN-bearing product on prescription from a licensed pharmacy.
Neither is a controlled substance. CompoundPlug supplies both strictly as research chemicals. See Research Use Only.
In Summary
Tirzepatide adds a second receptor and, in the one trial that tested them directly, produced greater weight reduction.
Semaglutide has the longer record, the cardiovascular outcome data, an oral formulation, and — in Canada — approved generics.
They are answering slightly different questions, and the trial evidence supports both statements.
- Semaglutide (SEMA) — 10mg. HPLC and mass-spec verified.
- Tirzepatide (TIRZ) — 10mg, 20mg, 30mg. HPLC and mass-spec verified.
- Retatrutide vs Tirzepatide — what a third receptor adds.
- GLP-1 Peptides — the full category.
Frequently Asked Questions
What is the difference between semaglutide and tirzepatide?
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). What the GIP arm actually contributes is still debated — it may act centrally, on adipose tissue, or simply by improving tolerability enough to permit higher effective dosing.
Which produced more weight loss in trials?
Tirzepatide, in the SURMOUNT-5 head-to-head trial of 751 participants over 72 weeks. This is one of the few direct comparisons in the field — most “X vs Y” claims rest on cross-trial inference.
Does semaglutide have anything tirzepatide doesn’t?
Yes. The SELECT trial produced cardiovascular outcome data — a hard outcome rather than a metabolic surrogate. Semaglutide also has an oral formulation (Rybelsus) and, in Canada, approved generics. Tirzepatide has neither.
Are both approved in Canada?
Yes. Semaglutide (Ozempic, Wegovy, Rybelsus, plus approved generics) and tirzepatide (Mounjaro, Zepbound) are all authorized prescription drugs carrying Drug Identification Numbers.
Is there a generic version?
Semaglutide, yes — Health Canada was the first G7 regulator to approve one. Tirzepatide, no.
Do they have different side effects?
No meaningful difference in the type of adverse effect is established. Both show the incretin class profile: gastrointestinal effects, dose-related, most commonly nausea, vomiting, and diarrhea.